Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 2
1968 2
1969 2
1970 2
1971 2
1972 5
1973 17
1974 12
1975 19
1976 15
1977 13
1978 13
1979 11
1980 10
1981 11
1982 24
1983 23
1984 31
1985 25
1986 19
1987 24
1988 17
1989 50
1990 41
1991 49
1992 41
1993 50
1994 51
1995 70
1996 53
1997 53
1998 58
1999 66
2000 72
2001 88
2002 84
2003 71
2004 65
2005 72
2006 74
2007 73
2008 72
2009 65
2010 73
2011 79
2012 88
2013 82
2014 89
2015 103
2016 85
2017 81
2018 76
2019 98
2020 89
2021 96
2022 86
2023 76
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

2,584 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma"
Page 1
How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA, Engert A. Eichenauer DA, et al. Blood. 2020 Dec 24;136(26):2987-2993. doi: 10.1182/blood.2019004044. Blood. 2020. PMID: 32877522 Free article. Review.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and clinical characteristics. Unlike the malignant cells in classical Hodgkin lymphoma, the disease-defining …
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pa …
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2022 Nov;97(11):1478-1488. doi: 10.1002/ajh.26717. Epub 2022 Sep 19. Am J Hematol. 2022. PMID: 36215668 Free article.
DIAGNOSIS: HL is composed of two distinct disease entities: classical HL and nodular lymphocyte-predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups of classical HL. ...
DIAGNOSIS: HL is composed of two distinct disease entities: classical HL and nodular lymphocyte-predominant HL. …
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL. Connors JM, et al. Nat Rev Dis Primers. 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. Nat Rev Dis Primers. 2020. PMID: 32703953 Review.
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in the tumour microenvironment. ...Diagnosis is based on histological and immunohistochemical analyses of tissue from a lymph node biopsy; the t …
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in t …
Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM. Ansell SM. Mayo Clin Proc. 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. Mayo Clin Proc. 2015. PMID: 26541251 Review.
This disease represents approximately 11% of all lymphomas seen in the United States and comprises 2 discrete disease entities--classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Within th …
This disease represents approximately 11% of all lymphomas seen in the United States and comprises 2 discrete disease entities …
Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2020 Aug;95(8):978-989. doi: 10.1002/ajh.25856. Epub 2020 Jun 8. Am J Hematol. 2020. PMID: 32384177 Free article.
DIAGNOSIS: Hodgkin lymphoma is composed of two distinct disease entities: classical HL and nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subg …
DIAGNOSIS: Hodgkin lymphoma is composed of two distinct disease entities: classical HL and nodular lymphocyte …
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF. Advani RH, et al. Blood. 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. Blood. 2021. PMID: 33827139 Free article. Clinical Trial.
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV and Nivo in cycle …
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/re …
Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.
Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Fan Z, et al. Am J Surg Pathol. 2003 Oct;27(10):1346-56. doi: 10.1097/00000478-200310000-00007. Am J Surg Pathol. 2003. PMID: 14508396
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has traditionally been recognized as having two morphologic patterns, nodular and diffuse, and the current WHO definition of NLPHL requires at least a partial nodular pattern. …
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has traditionally been recognized as having two m …
Hodgkin lymphoma.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J; NCCN Hodgkin Lymphoma. Hoppe RT, et al. J Natl Compr Canc Netw. 2011 Sep 1;9(9):1020-58. doi: 10.6004/jnccn.2011.0086. J Natl Compr Canc Netw. 2011. PMID: 21917626 No abstract available.
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
Eichenauer DA, Engert A. Eichenauer DA, et al. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):324-328. doi: 10.1182/asheducation-2017.1.324. Hematology Am Soc Hematol Educ Program. 2017. PMID: 29222274 Free PMC article. Review.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with an incidence of 0.1 to 0.2/100 000/y. ...Histologically, the disease-defining lymphocyte predominant cells consistently express CD …
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with an incidenc …
Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA, Engert A. Eichenauer DA, et al. Curr Opin Oncol. 2021 Sep 1;33(5):395-399. doi: 10.1097/CCO.0000000000000774. Curr Opin Oncol. 2021. PMID: 34224482 Review.
PURPOSE OF REVIEW: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B cell-derived malignancy. ...Treatment differs from classical Hodgkin lymphoma in some situations....
PURPOSE OF REVIEW: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B cell-derived malig …
2,584 results